Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept
查丹援引 DYNE-101、DYNE-251 的其他積極數據，將達因療法的目標股價從31美元上調至42美元；買入評級保持不變
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊